During this webinar, “CyberKnife Radiosurgery for Brainstem Lesions”, Dr. Wang will present SRS, hypofractionated stereotactic radiosurgery, and staged SRS for the brain stem lesions from brain metastasis, glioma to cavernous hemangioma, etc with Huashan CyberKnife Center’s experiences. The objective is to share the efficacy and safety with CyberKnife for brainstem lesions treatment.
Enmin Wang, M.D., Ph.D., Chief Physician, CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
Dr. Enmin Wang is a neurosurgeon with clinical interest in the treatment of central nervous system disease. He is one of neurosurgeons engaged in Leksell Gamma Knife radiosurgery in China since 1993. Up to now, he has treated more than 10000 patients with brain tumors or AVM using Leksell Gamma Knife radiosurgery. Since 2007, he has been engaged in CyberKnife Radiosurgery treatment, focusing on benign tumors of the central nervous system, cerebral arteriovenous malformations, brain metastases and recurrent gliomas. He is a Vice Chair of Radiosurgery Committee of International Chinese Federation of Neurosurgical Science. He is leader in the two clinical studies in glioma. One study is safety and efficacy of hypofractionated stereotactic radiosurgery with anlotinib targeted therapy for glioblastoma at first recurrence. Another clinical study is “Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial”.
Moderated by: Steve Braunstein, M.D., Ph.D., Associate Professor and Vice-Chair of Radiation Oncology, University of California San Francisco
Dr. Steve Braunstein is a radiation oncologist with a clinical interest in the treatment of the central nervous system, pediatric, soft tissue malignancies, and metastatic disease. He has expertise in modern radiation therapy techniques including stereotactic radiotherapy, intraoperative radiotherapy, and intensity-modulated radiation therapy. Dr. Braunstein earned his M.D. at New York University School of Medicine where he also obtained a Ph.D. studying key molecular pathways by which cancer cells mediate response to radiation therapy. He is a member of UCSF Brain Tumor Center, Pediatric Malignancies Program, and Sarcoma Program. At the national level, he serves on NRG and COG core leadership committees, involved in clinical trial design and implementation for a number of adult and pediatric malignancies. His research focus is the integration of modern multi-disciplinary therapies to improve outcomes while minimizing acute and long-term toxicity. He is also committed to the education of the next generation of radiation oncology leaders, serving as residency training program director.
